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OBJECTIVES: To evaluate the cost-effectiveness of
CYP2C9 genotyping for the management of anticoagula-
tion therapy in patients newly started on warfarin from
the provider’s perspective. METHODS: A decision tree
was designed to simulate, over 12 months, the outcomes
of patients newly started on warfarin associated with two
alternatives: 1) no genotyping (standard care group); and
2) CYP2C9 genotyping prior to initiation of warfarin
therapy (genotyping group). Each alternative could lead
to three possible outcomes: No event, bleeding, and
thromboembolic event (TE). Patients in the standard care
group would receive standard care of the anticoagulation
clinic (AC). In the genotyping group, intensiﬁed antico-
agulation service would be provided to patients with at
least one variant CYP2C9 allele while others would
receive standard AC care. The intensiﬁed AC service was
assumed to reduce all event rates by 50% and cost more
than standard service by 50%. The prevalence of
CYP2C9 polymorphism and event rates was derived from
literature. Cost of standard AC service and manage-
ment of events were estimated from the literature and the
Diagnosis-Related Groups charges. Sensitivity analysis
was conducted to examine the robustness of the model.
RESULTS: The cost per patient-year and event-free rate
per 100 patient-year of the genotyping group and the
standard care group were USD 1729 and 89%, and, USD
2068 and 85%, respectively. One-way sensitivity analysis
showed that the model was sensitive to variation of two
variables: rate of bleeding in patients with at least one
variant CYP2C9 allele (threshold value = 0.04 events per
100 patient-year) and the reduction of bleeding rate in
patients with at least one variant CYP2C9 allele with the
intensiﬁed service (threshold value = 10%). CONCLU-
SION: The genotyping group was less expensive and
more effective than the standard care group for the man-
agement of anticoagulation therapy in patients newly
started on warfarin.
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OBJECTIVE: To conduct an economic evaluation of
unfractionated heparin (UFH) compared with low mole-
cular weight heparin (LMWH) enoxaparin in acute 
coronary syndrome (ACS) treatment. METHODS: Two
group patients with ACS. Arm A: 23 patients with 
unstable angina (UA)—52.2% and non-Q-wave myocar-
dial infarction (NQWMI)—37.8% treated by UFH, 200
IU/kg/day. Arm B:—23 patients, 52.2% in UA and 37.8%
in NQWMI treated by enoxaparin 1mg/kg/twice a day.
All patients were treated by heparin up to remission
achievement. Economic evaluation was done by cost—
effectiveness analysis usage. The costs of the treatment
and resource utilization items were analyzed. Unit costs
were based on detailed data from the Moscow Obliga-
tory Insurance Fond (January 2003). The total direct
medical costs were calculated as a sum of costs for
follows: expenses on medicine and drug using, hospital
expenditures, diagnostic and laboratory tests, time allo-
cation. Achievement of stable remission of the process
was the effectiveness. RESULTS: The total direct medical
costs of Arm A came to 538,960 rubles and expenditures
for heparin usage were 10,000 rubles (1.8%) of them.
And for Arm B it was 457,072 rubles as total medical
costs and 53,146 rubles or 11.6% of them for enoxaparin
usage. Stable remission was 65% and 83% for Arms A
and B respectively. Serious side effects weren’t registered
at all. Cost effectiveness (CE) index for both groups was
calculated as CE = The total costs of whole treatment/
Effectiveness (% of remission) CE A = 360.5 rubles/% 
per patient. CE B = 239.43 rubles/% per patient. The 
Rate of Exchange was 31.5 rubles for USD$1. CON-
CLUSION: in spite of the high costs for LMWH in
compare to UFH this is evidence based way for approach-
ing necessary effect of patients in ACS with investment
saving.
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OBJECTIVES: To evaluate the total treatment cost and
cost-effectiveness of treatments for elderly patients with
acute myocardial infarction and patients for which treat-
ment starts later, in the Greek NHS. METHODS: Data
are coming from large RCTs evaluating the treatments
considered. Outcomes include all major health events
associated with an AMI. Trial data we extracted and used
to populate a decision analytic model that computes
events rates, survival and costs from AMI occurance till
death. The model reports results for patients above 75
and for patients for which treatments starts at least 4
hours after symptom onset. The database of a large Uni-
versity Hospital was analyzed to estimate in-patient and
outpatient costs associated with various events. Simula-
tion was used to test the robustness of the results.
RESULTS: For patients above 75 life time costs on
alteplase, reteplase and tenecteplase were estimated, at
€13.485, €13.400, and €13.824 respectively. Average sur-
vival was 1.8396, 1.8039, and 1.9325 years respectively.
Tenecteplase has marginally higher cost and outcomes.
Alteplase and tenecteplase dominate the second arm and
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the incremental-cost-per-life-year-saved of tenecteplase
over alteplase is about €3600, and for that reason it
should be preferred on the basis of its very cost-effective
ratio. For patients at the age of 62, for whom treatment
starts late the average cost and survival was €23.671,
€23.304, €24.343, and 7.9172, 7.7716, and 8.2093
respectively. The incremental cost of tenecteplase was
lower this time at €2.305. These results are based the
point estimates and in general terms they also hold true
when simulation is employed. CONCLUSIONS: The
treatments evaluated here are similar in respect of total
treatment costs, so that it is difﬁcult to distinguish
between them. If anything, tenecteplase is characterized
by a marginally better cost-effectiveness ratio.
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OBJECTIVE: To examine the cost-effectiveness (CE) of
atorvastatin compared to simvastatin in the treatment 
of patients with dyslipidemia in the Netherlands.
METHODS: The cost-effectiveness was evaluated using
effectiveness data from the LIZO trial, a 3-month clini-
cal trial in which patients were compared on milligram-
equivalent doses of either 20 or 40mg atorvastatin or
simvastatin. Short-term (three month) cost-effectiveness
was assessed based on the percentage of patients reach-
ing EAS or NCEP ATP-II LDL treatment targets, and drug
cost. These results were extrapolated to a 10-year period.
This long-term CE-evaluation assessed drug costs, CHD-
event costs, and life years gained. Patients reaching target
cholesterol levels and remaining on drug treatment were
assumed to have a maximum reduction in risk of CHD
events during the 10-year period; patients not reaching
target levels were assumed to have an average risk reduc-
tion for CHD-events. Risk calculation for CHD-events
was based on Dutch CBO-guidelines. Cardiac events were
assumed to occur after 5 years. One- and two-way sensi-
tivity analyses were performed. RESULTS: Short-term
cost-effectiveness analyses showed cost-effectiveness
between €51 and €422 per successfully treated patient.
The results of the long-term analyses indicated dominance
of the atorvastatin treatment in the 20mg group using
both EAS and NCEP-guidelines. For patients treated with
40mg, dominance was observed using NCEP-guidelines
and cost-effectiveness of €7,889 per life-year gained using
the EAS-guidelines. In the sensitivity analyses the results
were robust and below the €18,000 benchmark stated in
the Dutch guidelines, with the exception of time of occur-
rence of CHD events. CONCLUSION: This CE-analysis
regarding dyslipidemia treatment is the ﬁrst evaluation
conducted in the last 10 years in the Netherlands. The
study showed low cost-effectiveness for the short-term
evaluation and cost-savings for atorvastatin in compari-
son to simvastatin in 3 of the 4 evaluations in the long-
term CE-analyses.
CARDIOVASCULAR DISEASE—Quality of Life
Studies
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OBJECTIVES: Few measures are available for use in pul-
monary hypertension (PH), limiting outcome assessment
in this condition. Generic outcome measures are of
limited value due to their lack of PH-speciﬁcity. Two new
PH-speciﬁc instruments were developed; a HRQL (health
status) and a QoL measure. METHODS: Patients were
recruited from Papworth Hospital in the UK for unstruc-
tured interviews. Comments from patients were used to
create item pools for a HRQL and QoL measure. The
HRQL measure focuses on impairments (symptoms) and
disability (functioning) while the QoL measure focuses on
the impact of PH on patients’ abilities to meet their needs.
The measures were included in a postal survey. Rasch
analysis was used to reduce items and conﬁrm unidimen-
sionality of scales. Revised measures were then ﬁeld-
tested with PH patients. RESULTS: Thirty-ﬁve patients
were interviewed (M:F = 9:26). Ages ranged from 20–
80yrs (mean = 50yrs). Content analysis indicated a wide
impact of PH on HRQL and QoL. Seventy-nine patients
completed the postal survey (M:F = 20:54); age range
19–81yrs (mean = 52yrs). Rasch analyses showed all
scales (including the overall impairment scale and its sub-
scales: Breathlessness, Oedema, Energy, and Mood) ﬁtted
the model after deleting mis-ﬁtting items. All scales exhib-
ited good severity coverage and internal consistency
(Alpha); impairment = 0.79; disability = 0.93; QoL =
0.93. The 41-item impairment scale, 17-item functioning
scale, and 36-item QoL scale were ﬁeld-tested with 15
patients (M:F = 5:10); age range 25–72yrs (mean =
52yrs). Measures were found to be relevant, comprehen-
sible, and quick to complete (completion time range = 4–5
minutes). CONCLUSIONS: The new PH measures were
well-accepted by respondents who consider their content
comprehensive and relevant. A second postal survey is
under way to enable psychometric testing of the mea-
sures. The ﬁnal measures will be invaluable for outcome
assessment of PH patients.
